Myotonic dystrophy type 1 (DM1) is a rare genetic disorder, characterised by muscular dystrophy, myotonia, and other symptoms. DM1 is caused by the expansion of a CTG repeat in the 3'-untranslated region of DMPK. Longer CTG expansions are associated with greater symptom severity and earlier age at onset. The primary mechanism of pathogenesis is thought to be mediated by a gain of function of the CUG-containing RNA, that leads to trans-dysregulation of RNA metabolism of many other genes.
Introduction yielding 42 genes with confirmed AS defects. Nakamori et al. report several technical obstacles with this approach, with the initial 76 version of their pipeline suffering from as many as 80% putative AS defects failing to 77 replicate with Reverse Transcription-PCR. Further analysis suggested that this occurred 78 when "signal intensity for the entire transcript or a particular exon was low", "overall 79 expression of a transcript was strongly up-or down-regulated in DM1 relative to 80 normal controls", or "signal intensity of an exon was inappropriately high relative to 81 other exons in the same transcript" [8] . 82 Batra et al. [9] re-used the dataset of Nakamori et al. [8] and used similar techniques 83 to filter down the data, in a search for genes with dysregulated APA. Their selection 84 criteria focused on probesets with over 2-fold change in DM1 or DM2 vs. unaffected 85 controls, excluding genes that were represented by ≤ 5 probesets, retrogenes and 86 non-protein coding genes, which resulted in pre-selection of 438 probesets. The authors 87 performed visual inspection of all pre-selected probesets identifying 123 APA events 88 belonging to 80 genes. 89 Evaluating Potential Biomarkers of DM1 90 We propose that predictors are a suitable statistical tool, which can find applications in 91 DM1 research and clinical practice. As described before, DM1 case/control status [8, 9] 92 leaves a discernible pattern in the mRNA profiles of muscle samples. In this research, 93 rather than to work with the DM1 status as a binary variable, we look at DM1 as a 94 spectrum disease, severity of which is quantified by the length of the DM1 CTG repeat 95 in any individual patient. We propose that it is possible to capture the effect, which the 96 length of this repeat has on mRNA expression in muscle into a simple statistical model, 97 based on linear regression. Using the model we can predict the size of the DM1 CTG 98 repeat from the mRNA profile significantly better than a random predictor. We propose 99 that the model can serve as a valuable tool in evaluating efficacy of any treatment for 100 DM1 as such treatment enters pre-clinical or clinical trials, by enabling investigators to 101 directly quantify the treatment effect as measured by effective reduction of DM1 CTG 102 repeat length. treatments will not be an actual reduction in the repeat length (with notable exception 105 of candidate treatments based on gene editing). Rather, an "effective reduction" is a 106 reduction of "effective repeat length", i.e. repeat length as judged by the degree of 107 splicing changes. This can be demonstrated with an example of a patient with a certain 108 pre-treatment repeat length, and both physiological and molecular symptoms 109 characteristic for that repeat length. If such patient were to undergo an effective 110 treatment we would expect these symptoms to be partially reversed, and our predictive 111 framework to predict a shorter repeat length than the patient's actual repeat length.
112
Subject to correctness of our understanding of the molecular pathophysiology of the 113 splicing changes, which we rely on to predict the effective repeat length, we expect that 114 the reversal of the splicing changes would occur immediately after the release of 115 inactivated AS and APA factors, such as MBNL1. This release should in turn happen 116 immediately after a candidate therapeutic were to reach a clinically significant level in 117 the relevant tissue. We expect this to happen on a timescale of days to weeks, unlike 118 the reversal of physiological symptoms, which we would expect to happen on longer 119 timescales. case-control status, specifically, the mode of the CTG repeat length from blood 151 (MAL). We also estimate the repeat length at birth (Progenitor Allele Length, 152 PAL) using a previously developed method [19] . transcription clusters, which correspond to the entire genes.
176
Data preparation and analysis 177 We designed and built a pipeline, programmed in Python, which has the following data 178 preparation capabilities: Reading raw Affymetrix CEL v4 files (peer reviewed and 179 merged into Biopython [21, 22] ); quantile normalisation and log2 transformation of 180 intensity data; strict annotation of Affymetrix probes using GENECODE v26 lift 37 181 through selecting probes corresponding to annotated GENECODE transcripts of type 182 "protein coding", annotated genes of type "protein coding" and exons of type "CDS" or 183 "UTR". Appendix S1 Appendix gives full source code, user manual and additional 184 explanation of each step of this pipeline.
185
The pipeline's final output are two directories: "experiment muscle" and 186 "experiment blood", each containing 19,826 files, whose filenames correspond to HGNC 187 gene names. The following is a two-line excerpt from one of such files,
188
"experiment blood/TNNI1". Data for several patients has been removed to enhance In each file, the first row is a header containing tab-separated names of data or 200 metadata types contained in a given column. Below we give a brief description of some 201 of the data or metadata types:
202
• seq5to3 -unlike Affymetrix we always report the sequence in 5' to 3' direction, 203 and always with regards to the plus strand, even if the coding sequence is 204 contained on the minus strand.
205
• genecode left, genecode right -these are genomic coordinates as reported by a 206 reference assembly (GRCh37). Following convention, first coordinate is 1-based, 207 and coordinates are left-, right-inclusive.
208
• x, y give the x and the y coordinates of probes on the chip.
209
• patient * -these are quantile normalised and log2-transformed intensities at the 210
given probe for the given study participant.
211
Each subsequent row contains data and metadata for a single probe. 212 We develop a predictive model, which closely follows that of Lee et al. [17] . We work 213 with pre-selected sets of genes that act as candidate biomarkers. For this purpose, we 214 look at the following collections of genes: 215 1. A previously identified selection of genes, listed in S2 Appendix and identified by 216 Nakamori et al. [8] as genes whose AS is disrupted in DM1. We codename these 217 genes "DM1-AS". Batra et al. [9] as genes whose AP is disrupted in DM1. We codename these genes 220 "DM1-APA". The overlap of this list of genes with DM1-AS is a list of two genes: 221 LDB3, MBNL2.
particular gene post-hoc and its true predictive value might have been influenced by issues related to multiple hypotheses testing. An additional validation study would have 279 to be performed before drawing any conclusions on the performance of TNNI1 as a DM1 280 biomarker.
281
A safer belief can be assigned to the predictive value of "DM1-AS" and "DM1-APA" 282 as both sets of genes have been previously implicated in DM1 [9] , and we can detect 283 strong signal from both sets of genes, with models based on these genes capturing 284 respectively 30% and 15% of MAL variance in our study group.
285
One has to note an interesting observation relating to the "curse of dimensionality" 286 and the performance of our PLSR-based model. Although TNNI1 is a subset of 287 DM1-APA, TNNI1 on its own is a much better predictor than DM1-APA, as increasing 288 the number of genes (features) increases the dimensionality of our data and worsens the 289 prediction delivered by the PLSR model.
290
A single run of 10,000 repetitions of a simulation can be visualised by plotting the 291 predicted value of MAL against the actual, adding a small amount of random noise on 292 the x-axis. For DM1-AS in muscle, such visualisation is given in Fig 1. 293
In blood we cannot detect significant signal for most candidate biomarkers, with R 2 294 not significantly respectively greater and lower than would be expected by chance, 295 except in one case, DM1-APA, whose R 2 and p-value are 0.15 and 0.0564 respectively. 296
Full R 2 and (uncorrected) p-values are given in muscle and blood, the set of genes DM1-AS is the strongest predictor if we limit our 307 consideration to predictors chosen a-priori (i.e. excluding TNNI1).
308
A potential source of criticism could be that the effect observed is a technical effect 309 due to the choice or the implementation of the mathematical model used (PLSR). We 310 August 7, 2019 13/28 thus re-ran the analysis as described before in Data preparation and analysis using three 311 mathematically distinct models: lasso, random forest regression and linear regression. Table 3 . 10000 repetitions of a simulation predicting MAL from muscle, using DM1-AS as a predicting set and a selection of mathematical models linear regression PLSR lasso random forest R 2 0.291 0.289 0.286 0.149 p-value 0.00418 0.00434 0.00454 0.0478
As this work is the first presentation of the DMBDI dataset, we recognise that further 366 work might build on the dataset in ways which differ from our approach and cannot be 367 predicted at the current stage of our understanding of DM1-related AS/APA changes. 368
To facilitate this, we would like to propose a tool which on one hand allows for informal, 369
interactive and exploratory analysis of the dataset and on the other allows the flexibility 370 of building a custom analysis -just like the one presented here.
371
The tool is available online [23] , and is implemented as a jupyter notebook with 372 custom visualisation of filtered and normalised DMBDI data. The flexibility of the tool 373 comes at a cost. In order to support arbitrary bioinformatics analyses we have to 374 support arbitrary code execution, which in turn requires protecting the tool with a 375 password. We will share the password with any bona fide researcher upon request. A 376 walk-through video showcasing the capabilities of the tool is available on youtube [24] . 377
The major capability of the tool is the ability to produce "railway plots". Railway of the isoform), and is not a CDS incomplete transcript, which allows us to strengthen 404 our belief in the fact that this is a biologically functional/ protein-coding transcript, 405 which can play a role in the DM1-related AS/APA changes.
406
Finally, and returning back to statistics, we can ask whether high significance of the 407 splice-out event is a result of multiplicity effect, given that the gene was chosen post-hoc 408 from a pool of candidate biomarker genes as determined by Batra et al. and Nakamori 409 et al. [8, 9] . A standard approach here would be to combine the data from the discovery 410 dataset with the data from the replication dataset, compute a more powerful test, and 411 apply multiplicity correction. This is not possible in this case as the discovery dataset, 412
underlying both studies is a case-control dataset, whereas our dataset captures DM1 shows that the combined p-value based on the discovery dataset and our dataset is possibly observed changes in AS/APA are partly attributable to these physiological 447 differences in DM1 as opposed to purely biomolecular differences. The structure of this 448
counter-argument could be as follows:
expressed in skeletal muscle, not fat.
Conclusion 490
In this study we design and build a model based on PLSR, which can explain as much 491 as 28.9% of the variance in DM1 CTG trinucleotide expansion from mRNA splicing 492 data. Such explainability is only obtained when the model is trained on expression data 493 from genes previously identified by Nakamori et al. [8] as having disrupted AS on data 494 obtained from muscle samples. We show how such model could be used in a clinical comments on multiple revisions of this manuscript, as well as performing initial analysis 576 and quality control on blood and muscle microarray samples. We would also like to 577 thank Anna Casasent (nee Unruh) for performing quality control on blood and muscle 578 microarray samples. 
